BioMarin Pharmaceutical Inc.: Enhancement of Enzyme Replacement Therapy (ERT) Portfolio and Advancement of Gene Therapy & Innovation

BioMarin Pharmaceutical Inc. delivered a robust performance in the third quarter of 2024, highlighting significant year-on-year growth across its product portfolio. The company reported a record revenue of $746 million, which represents a 28% jump compared to the same period in 2023. This upward trend was predominantly fueled by a 50% surge in VOXZOGO sales, a treatment for achondroplasia, thanks to increased market penetration in the U.S. and expansions into new geographical locations.